Comparative in vitro study of different peritoneal dialysis solutions on cytokine production by peripheral blood mononuclear cells

Nephron - Clinical Practice

Volumn 113, Issue 4, 2009, Pages

  Bacharaki, Dimitra ^a   Thodis, Elias ^a   Passadakis, Ploumis ^a   Kantartzi, Konstantia ^a   Kriki, Pelagia ^a   Vargemezis, Vassilis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Biocompatibility; IL 6; Peritoneal dialysis; Peritoneal solutions; TNF

Indexed keywords

AMINO ACID; GLUCOSE; HYPERTONIC SOLUTION; ICODEXTRIN; INTERLEUKIN 6; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PYRUVIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SUPERNATANT;

ADULT; CELLS, CULTURED; CYTOKINES; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PERITONEAL DIALYSIS;

EID: 69549116043     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235951     Document Type: Article

References (41)

1. Gokal R: Peritoneal dialysis in the 21st century: An analysis of current problems and future developments. J Am Soc Nephrol 2002; 13:S104-S116.
2. Coles GA, Williams JD, Topley N: Peritoneal inflammation and long term changes in peritoneal structure and function; in Gokal R, Khanna R, Krediet RT, Nolph KD (eds): Textbook of Peritoneal Dialysis, ed Boston, Kluwer Academic Publishers, 2000, pp 565-583.
3. Duwe AK, Vas SI, Weatherhead JW: Effects of the composition of peritoneal dialysis fluids on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immunity 1981; 33: 130-135.
4. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C: Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61: 375-386.
5. Martis L: Industry perspectives on biocompatibility of peritoneal dialysis solutions. Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1995; 15; 7(suppl):S96-S99.
6. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12: 2434-2441.
7. McIntyre CW: Update on peritoneal dialysis solutions. Mini review. Kidney Int 2007; 71: 486-490.
8. Holmes CJ, Faict D: Peritoneal dialysis solution biocompatibility: Definitions and evaluation strategies. Kidney Int 2003; 64(suppl 88):S50-S56.
9. Hoff CM: In vitro biocompatibility performance of Physioneal. Kidney Int 2003; 64 (suppl 88):S57-S74.
10. Ter Wee PM, Beelen RHJ, Van den Born J: The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int 2003; 64(suppl 88):S75-S83.
11. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams GT, for the Biopsy Registry Study Group: The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int 2003; 64(suppl 88):S43-S49.
12. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT, on behalf of the Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
13. Godfrey K: Comparing the means of several groups; in Baillard JC, Mosteller F (eds): Medical Uses of Statistics., ed 2, Boston, NEJM Books, 1992.
14. Plum J, Schoenicke G, Grabensee B: Osmotic agents and buffers in peritoneal dialysis solution: Monocyte cytokine release and in vitro cytotoxicity. Am J Kidney Dis 1997; 30: 413-422.
15. Plum J, Lordnejag MR, Grabensee B: Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998; 54: 224-235.
16. Jorres A, Gahl GM, Frei U: In vitro studies of the effect of dialysis solutions on peritoneal leucocytes. Perit Dial Int 1995; 15(suppl): S41-S46.
17. Carozzi S, Nasini MG, Ravera M, Sanna A, Tirotta A, Lamperi S: Peritoneal dialysis effluent, cytokine levels and peritoneal mesothelial cell viability in CAPD: A possible relationship. Adv Perit Dial 1997; 13: 7-12.
18. Wieslander AP, Kjellstrand PTT, Rippe B: Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations. Perit Dial Int 1995; 15(suppl):S52-S60.
19. Topley N: What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions? Perit Dial Int 1995; 15 (suppl):S101-S108.
20. Clemedson C, McFarlane-Abdulla E, Andersson M, et al.: MEIC evaluation of acute systemic toxicity for the first 30 reference chemicals: Part II. In vitro results from the 68 methods and a comparative cytotoxicity analysis. Altern Lab Anim 1996; 24(suppl 1): 273-311. (Pubitemid 126467903)
21. Clemedson C, et al: MEIC evaluation of acute systemic toxicity for the first 30 reference chemicals: Part I. Methodology of the 68 in vitro cytotoxicity assays. Altern Lab Anim 1996; 24(suppl 1):251-272.
22. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk H-D: Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor- . J Exp Med 1995; 181: 1887-1892.
23. Friedlander MA, Hilbert CM, Ching Wu Y, Rich EA: Role of dialysis modality in responses of blood monocytes and peritoneal macrophages to endotoxin stimulation. Am J Kidney Dis 1993; 22: 11-23.
24. Breborowicz A, Oreopoulos DG: Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications. Perit Dial Int 1997; 17(suppl 2): S37-S41.
25. Garosi G, Di Paolo N: Recent advances in peritoneal morphology: The milky spots in peritoneal dialysis. Adv Perit Dial 2001; 17: 25-28.
26. Cendoroglo M, Sundaram S, Jaber BL, Pereira BJG: Effect of glucose concentration, osmolarity and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro. Am J Kidney Dis 1998; 31: 273-282.
27. Jorres A, Topley N, Gahl GM: Biocompatibility of peritoneal dialysis fluids. Int J Artif Organs 1992; 15: 79-83.
28. Martikainen TA, Teppo AM, Gronhagen-Riska C, Ekstrand AV: Glucose-free dialysis solutions: Inductors of inflammation or preservers of peritoneal membrane? Per Dial Int 2005; 25: 453-460. (Pubitemid 41448400)
29. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh, HA: Assessment of the effectiveness, safety and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Peri Dial Int 2000; 20(suppl 2): S106-S113.
30. Mackenzie R, Holmes CJ, Jones S, Williams JD, Topley N: Clinical indices of in vivo biocompatibility: The role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney Int 2003; 64(suppl 88):S84-S93.
31. Zemel D, Imholz ALT, De Waart DR, Dinkla C, Struijk DG, Krediet RT: Appearance of tumor necrosis-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46: 1422-1430.
32. Dobbie JW: Durability of the peritoneal membrane. Peri Dial Int 1995; 15(suppl): S87-S92.
33. Dobbie JW: Editorial: From philosopher to fish: The comparative anatomy of the peritoneal cavity as an excretory organ and its significance for peritoneal dialysis in man. Peri Dial Int 1988; 8: 3-6.
34. Wieczorowska-Tobis K, Polubinska A, Breborowicz A, Oreopoulos DG: A comparison of the biocompatibility of phosphate-buffered saline and Dianeal 3,86% in the rat model of peritoneal dialysis. Adv Perit Dial 2001; 17: 42-46.
35. Styszynski A, Podkowka R, Wieczorowska-Tobis K, Kwiatkowska B, Ksiazek K, Breborowicz A, Oreopoulos DG: Glucose suppresses peritoneal inflammatory reactions and mesothelial hyperplasia caused by intraperitoneal saline infusion. Adv Perit Dial 2002; 18: 21-25.
36. Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HAT, Peers EM, Oe PL, ter Wee PM: Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime well for two years. Peri Dial Int 2000; 20: 174-180.
37. Brunkhorst R, Mahiout A: Pyruvate neutralizes peritoneal dialysis cytotoxicity: Maintained integrity and proliferation of cultured human mesothelial cells. Kidney Int 1995; 48: 177-181.
38. Srivastava SK, Ramana KV, Bhatnagar A: Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005; 26: 380-392.
39. Vardhan A, Zweers MM, Gokal R, Krediet RT: A solutions portfolio approach in peritoneal dialysis. Kidney Int 2003; 64(suppl 88): S114-S123.
40. Zhou FQ: Advantages of pyruvate over lactate in peritoneal dialysis solutions. Acta Pharmacol Sin 2003; 22: 385-392.
41. Mahiout A, Matata BM, Brunkhorst R: Effect of glucose and pyruvate in acidic and non-acidic peritoneal dialysis fluids on leucocytes cell function. Kidney Int 1997; 51: 860-867.